Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.

Journal:

The Journal of antimicrobial chemotherapy, Volume: 72, Issue: 3

Published:

March 1, 2017

PMID:

27999020

Authors:

Gregory T Robertson GT, Michael S Scherman MS, David F Bruhn DF, Jiuyu Liu J, Courtney Hastings C, Michael R McNeil MR, Michelle M Butler MM, Terry L Bowlin TL, Robin B Lee RB, Richard E Lee RE, Anne J Lenaerts AJ

Access Paper

DOI: 10.1093/jac/dkw467

PMID: 27999020

Abstract:

New drug regimens employing combinations of existing and experimental antimicrobial agents are needed to shorten treatment of tuberculosis (TB) in humans. The spectinamides are narrow-spectrum semisynthetic analogues of spectinomycin, modified to avoid intrinsic efflux by Mycobacterium tuberculosis . Spectinamides, including lead 1599, have been previously shown to exhibit a promising therapeutic profile in mice as single agents. Here we explore the in vivo activity of lead spectinamides when combined with other agents.